Drug Discovery World

MARCH 10, 2023

China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for enfortumab vedotin for urothelial cancer. In China, the incidence rate of bladder cancer in 2020 ranked 12th among all cancers, with an estimated 85,649 new cases that year. 100,000 cases, or 235,393 cases.

Pharmacokinetics 130

Pharmacokinetics Drugs Licensing Licensing 130

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial. James Miessler.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

Drug Discovery World

AUGUST 4, 2022

Biopharmaceutical group Sosei will work together with AbbVie on a drug discovery project to discover, develop and commercialise small molecules that target neurological diseases. . Abbvie has the option to license three programmes at this stage and if so, will be responsible for clinical,? Sosei will put forward its Heptares’?StaR

Structure Based Drug Design (SBDD) 130

Structure Based Drug Design (SBDD) Small Molecule Drugs Licensing 130

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

The Pharma Data

DECEMBER 13, 2020

(Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the company conducted a Type B Meeting for omidubicel with the U.S. Food and Drug Administration (FDA) on Friday, December 11, 2020. About Omidubicel. About Gamida Cell.

Licensing 52

Licensing Licensing Clinical Trials FDA 52

Drug Discovery World

SEPTEMBER 21, 2022

LN is a severe manifestation of systemic lupus erythematosus (SLE), a chronic and debilitating autoimmune disease that is suggested to cause irreversible nephron loss. Up to 210 in 100,000 people in Europe live with SLE and 40-60% of those are at risk of developing LN during their lifetime. .

Treatment 130

Treatment Licensing Licensing Pharmaceuticals 130

The Pharma Data

MAY 7, 2021

under an Emergency Use Authorization (EUA) granted by the FDA on December 11, 2020. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. The Pfizer-BioNTech COVID-19 Vaccine is currently available in the U.S. AUTHORIZED USE IN THE U.S.: IMPORTANT SAFETY INFORMATION FROM U.S.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

DECEMBER 20, 2020

Interventional treatment for mitral regurgitation is considered to be one of the most challenging areas in the field of structural heart disease, yet also represents huge market potential. The terms also allow cross-licensing on future improvements of the products, encouraging both companies to focus on innovations. About HighLife.

Licensing 40

Licensing Licensing Production Treatment 40

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Pharmaceuticals Pharmaceutical Companies 40

Drug Discovery World

AUGUST 2, 2022

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma. . Recurrent glioma patients have poor prognosis with a median?

Trials 130

Trials FDA Immune Response Clinical Trials 130

Drug Discovery World

FEBRUARY 28, 2024

With the safety of MOv18 IgE having been established in cancer patients, biotechnology company Epsilogen has licensed the drug and will continue its clinical development following this successful clinical trial. Research into new cancer drugs remain strong.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 11, 2020

. Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment of ENPP1 deficiency. 12, 2020 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. Received Rare Pediatric Disease Designation and Fast Track Designation from the U.S. BOSTON, Nov.

Clinical Trials 40

Clinical Trials Trials Disease FDA 40

The Pharma Data

AUGUST 17, 2020

Food and Drug Administration clearance in May 2020 for its investigational new drug application to develop DF6002. In addition, Dragonfly has an ongoing Phase 1/2 clinical trial for patients with advanced solid tumors, which began in July 2020. Dragonfly received U.S. About Bristol Myers Squibb. About Dragonfly.

Licensing 52

Licensing Licensing Production Clinical Trials 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 10:45 UTC. –( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2020. 2020. for the third quarter of 2020. . for the third quarter of 2020. KENILWORTH, N.J.–(

Vaccine 40

Vaccine Trials Licensing Licensing 40

The Pharma Data

OCTOBER 27, 2020

28, 2020 /PRNewswire/ — ReVision Therapeutics, Inc., 28, 2020 /PRNewswire/ — ReVision Therapeutics, Inc., Stargardt disease is a devastating genetic disorder that affects central vision with no approved treatment options. . RIDGEWOOD, N.J. , About reVision Therapeutics, Inc.

Disease 52

Disease Treatment FDA Licensing 52

The Pharma Data

NOVEMBER 18, 2020

19, 2020 /PRNewswire/ — OBI Pharma, Inc. “Based upon our anti-Globo H targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have presentations on the progress of our trial presented at ESMO-Asia 2020 for our novel therapeutic cancer vaccine, OBI-833.” TAIPEI, Taiwan , Nov. About OBI Pharma.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

NOVEMBER 5, 2020

5, 2020 /PRNewswire/ — Third quarter 2020 revenues increased 32% to $2.29 Third quarter 2020 EYLEA ® U.S. Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07 Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07

Production 52

Production FDA FDA Approval Trials 52

The Pharma Data

OCTOBER 27, 2020

28, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended September 30, 2020. ” THIRD QUARTER 2020 FINANCIAL RESULTS. .” ” THIRD QUARTER 2020 FINANCIAL RESULTS. 2020. 2020.

FDA 40

FDA Production Licensing Licensing 40

The Pharma Data

NOVEMBER 4, 2020

5, 2020 11:00 UTC. NASDAQ: CNCE) today reported financial results for the third quarter of 2020. Our team has diligently and effectively executed on our plan, and I’m pleased that we have achieved our stated 2020 pipeline milestones. Initiated CTP-543 THRIVE-AA1 Phase 3 Trial in November 2020. LEXINGTON, Mass.–(

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Small Molecule 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). Dementia due to Alzheimer’s disease is the most common form of dementia, accounting for 60 to 80 percent of all cases 1.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

DECEMBER 16, 2020

17, 2020 09:00 UTC. NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., The disease is highly heterogeneous, affecting a wide range of organs and tissue systems. VICTORIA, British Columbia & ROCKVILLE, Md.–(

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

The Pharma Data

NOVEMBER 4, 2020

Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared toSame Periods of 2019 Despite COVID-19 Headwinds. Key A chievements in Third Quarter 2020 (and recent weeks). Court of Appeals for the Federal Circuit upheld the March 2020 U.S.

Production 40

Production FDA Trials Licensing 40

The Pharma Data

OCTOBER 26, 2020

27, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. NEW YORK, Oct. Founder and Chief Executive Officer of Prevail. “FDA

FDA 40

FDA Disease Treatment Therapies 40

Drug Discovery World

OCTOBER 12, 2022

DDW sits down with Mark Matson, Senior Solution Specialist for Sensor Cloud at Medidata, a Dassault Systèmes company, about the use of digital biomarkers in life sciences and how they can help advance our understanding of disease. . Is this a new way of looking at and understanding disease? . How do we define digital biomarkers? .

Clinical Trials 130

Clinical Trials Trials Disease Clinical Research 130

Drug Discovery World

AUGUST 31, 2022

To ensure equitable access for its Covid-19 vaccine, in October 2020, Moderna pledged not to enforce its Covid-19 related patents while the pandemic continued. However, it expected other companies to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets.

Vaccine 130

Vaccine RNA Licensing Licensing 130

The Pharma Data

DECEMBER 14, 2020

14, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), today announced the pricing of an underwritten public offering of 6,320,000 shares of common stock at a public offering price of $43.50 NEW YORK, Dec.

Clinical Trials 40

Clinical Trials Clinical Development Production Trials 40

New Drug Approvals

SEPTEMBER 8, 2024

4] [6] The applicant for this medicinal product is Ascendis Pharma Bone Diseases A/S. [4] 2] Palopegteriparatide was granted an orphan drug designation by the US Food and Drug Administration (FDA) in 2018, [7] and by the EMA in 2020. [8] 4] [6] The applicant for this medicinal product is Ascendis Pharma Bone Diseases A/S. [4]

FDA 62

FDA International FDA Approval Trials 62

The Pharma Data

NOVEMBER 6, 2020

06, 2020 (GLOBE NEWSWIRE) — Today, the U.S. The Advisory Committee also voted 0 yes, 7 no and 4 uncertain on the question, “Does Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”, CAMBRIDGE, Mass. and TOKYO, Nov. About Aducanumab.

Disease 40

Disease FDA Clinical Trials Licensing 40

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. INDIANAPOLIS , Oct.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

Drug Target Review

JULY 19, 2023

Most vaccines cannot be self-administered, so distribution requires access to trained healthcare services – a big problem in developing countries, which is where infectious disease burdens are highest. A leading company in this field, Seattle’s Lumen Bioscience, is best known for its orally delivered antibodies targeting diseases such as C.

Vaccine 96

Vaccine Engineering Disease Virus 96

The Pharma Data

OCTOBER 27, 2020

28, 2020 (GLOBE NEWSWIRE) — Passage Bio, Inc. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease (RPD) designations to PBKR03 for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). About Krabbe Disease. PHILADELPHIA, Oct.

Disease 40

Disease FDA Treatment Clinical Trials 40

The Pharma Data

OCTOBER 29, 2020

If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease. 30, 2020 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai, Co., CAMBRIDGE, Mass. and TOKYO, Oct.

Marketing 40

Marketing Disease Clinical Trials Treatment 40

Drug Discovery World

JULY 20, 2023

In September 2020, due to the pressure to find a medical interventions against SARS-Cov-2, there were 2553 active clinical trials into drugs to treat Covid-19, many including antivirals like tenofovir, ivermectin and chloroquine.

Clinical Pharmacology 100

Clinical Pharmacology Clinical Trials Drugs Trials 100

Drug Discovery World

MARCH 29, 2023

UMNs have been defined in the context of the draft as diseases where there’s a lack of good treatments, and which have a high burden 3. For rare disease drugs, a variable RDP period of five, nine, or ten years, depending on the novelty of the drug.

Clinical Trials 130

Clinical Trials Biosimilars Pharma Companies Production 130